187 related articles for article (PubMed ID: 32984055)
1. Successful Treatment of Chidamide and Cyclosporine for Refractory/Relapsed Angioimmunoblastic T Cell Lymphoma With Evans Syndrome: A Case Report With Long-Term Follow-Up.
Zhu F; Li Q; Pan H; Xiao Y; Liu T; Liu X; Li J; Wu G; Zhang L
Front Oncol; 2020; 10():1725. PubMed ID: 32984055
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic effect of chidamide on relapsed refractory angioimmunoblastic T-cell lymphoma: A case report and literature review.
Jin J; Zheng C; Wu S
Medicine (Baltimore); 2018 Jan; 97(2):e9611. PubMed ID: 29480865
[TBL] [Abstract][Full Text] [Related]
3. CD56+ angioimmunoblastic T-cell lymphoma with evans syndrome : a case report and review of the literature.
Sekiguchi Y; Shimada A; Imai H; Wakabayashi M; Sugimoto K; Nakamura N; Sawada T; Komatsu N; Noguchi M
J Clin Exp Hematop; 2013; 53(1):37-47. PubMed ID: 23801132
[TBL] [Abstract][Full Text] [Related]
4. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.
Shi Y; Dong M; Hong X; Zhang W; Feng J; Zhu J; Yu L; Ke X; Huang H; Shen Z; Fan Y; Li W; Zhao X; Qi J; Huang H; Zhou D; Ning Z; Lu X
Ann Oncol; 2015 Aug; 26(8):1766-71. PubMed ID: 26105599
[TBL] [Abstract][Full Text] [Related]
5. Comparison of chemotherapy and chidamide combined with chemotherapy in patients with untreated angioimmunoblastic T-cell lymphoma.
Gu S; Wang X; Zhou J; Du S; Niu T
Front Oncol; 2024; 14():1373127. PubMed ID: 38655138
[TBL] [Abstract][Full Text] [Related]
6. Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T-cell lymphoma in a Chinese population: A multicenter phase II trial.
Wang Y; Zhang M; Song W; Cai Q; Zhang L; Sun X; Zou L; Zhang H; Wang L; Xue H
Am J Hematol; 2022 May; 97(5):623-629. PubMed ID: 35170082
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Effect of CAOLD Chemotherapy Regimen on Patients With Relapsed/Refractory Angioimmunoblastic T-Cell Lymphoma: A Case Study.
Liu Y; Li P; Qian L
Front Oncol; 2021; 11():758445. PubMed ID: 35047389
[TBL] [Abstract][Full Text] [Related]
8. Modified ESHAP regimen for relapsed/refractory T cell lymphoma: a retrospective analysis.
Kogure Y; Yoshimi A; Ueda K; Nannya Y; Ichikawa M; Nakamura F; Kurokawa M
Ann Hematol; 2015 Jun; 94(6):989-94. PubMed ID: 25687839
[TBL] [Abstract][Full Text] [Related]
9. Cyclosporine, prednisone, and high-dose immunoglobulin treatment of angioimmunoblastic T-cell lymphoma refractory to prior CHOP or CHOP-like regimen.
Chen XG; Huang H; Tian Y; Guo CC; Liang CY; Gong YL; Zou BY; Cai RQ; Lin TY
Chin J Cancer; 2011 Oct; 30(10):731-8. PubMed ID: 21959050
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr Virus-Positive Adrenal Diffuse Large B-Cell Lymphoma after Treatment for Angioimmunoblastic T-Cell Lymphoma.
Hashimoto A; Asai S; Tanaka Y; Shinzato I
Eur J Case Rep Intern Med; 2021; 8(10):002533. PubMed ID: 34790617
[TBL] [Abstract][Full Text] [Related]
11. Diffuse large B-cell lymphoma in patient after treatment of angioimmunoblastic T-cell lymphoma.
Skugor ND; Perić Z; Vrhovac R; Radić-Kristo D; Kardum-Skelin I; Jaksić B
Coll Antropol; 2010 Mar; 34(1):241-5. PubMed ID: 20432757
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of chemotherapy-refractory angioimmunoblastic T cell lymphoma with cyclosporin A.
Kobayashi T; Kuroda J; Uchiyama H; Matsumoto Y; Horiike S; Taniwaki M
Acta Haematol; 2012; 127(1):10-5. PubMed ID: 21986307
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic efficacy of cyclosporin A for refractory angioimmunoblastic T cell lymphoma].
Mori M; Inoue D; Arima H; Takiuchi Y; Nagano S; Kimura T; Shimoji S; Nagai Y; Tabata S; Yanagita S; Matsushita A; Nagai K; Imai Y; Takahashi T
Rinsho Ketsueki; 2010 May; 51(5):332-8. PubMed ID: 20534954
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment with lenalidomide plus chidamide combination therapy in 3 heavily treated patients with non-Hodgkin lymphoma: Three cases report.
Hu S; Zou D; Zhou D; Zhang Y; Wang W; Zhang W
Medicine (Baltimore); 2020 Oct; 99(43):e22788. PubMed ID: 33120793
[TBL] [Abstract][Full Text] [Related]
15. Secondary cutaneous Epstein-Barr virus-associated diffuse large B-cell lymphoma in a patient with angioimmunoblastic T-cell lymphoma: a case report and review of literature.
Yang QX; Pei XJ; Tian XY; Li Y; Li Z
Diagn Pathol; 2012 Jan; 7():7. PubMed ID: 22260632
[TBL] [Abstract][Full Text] [Related]
16. Salvage camrelizumab for an intractable NK/T cell lymphoma patient with two instances of intestinal perforation: a case report and literature review.
Xia Y; Li QH; Liu T; Liu XX; Pan HX; Zhang LL; Zhu F
Eur Rev Med Pharmacol Sci; 2023 May; 27(10):4570-4577. PubMed ID: 37259738
[TBL] [Abstract][Full Text] [Related]
17. Cyclosporine for angioimmunoblastic T-cell lymphoma: a literature review.
Ohmoto A; Fuji S
Expert Rev Hematol; 2019 Nov; 12(11):975-981. PubMed ID: 31393197
[No Abstract] [Full Text] [Related]
18. Hemophagocytic lymphohistiocytosis after autologous stem cell transplantation in angioimmunoblastic T-cell lymphoma: A case report.
Zhang ZR; Dou AX; Liu Y; Zhu HB; Jia HP; Kong QH; Sun LK; Qin AQ
World J Clin Cases; 2023 Jun; 11(17):4072-4078. PubMed ID: 37388798
[TBL] [Abstract][Full Text] [Related]
19. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.
Morschhauser F; Fitoussi O; Haioun C; Thieblemont C; Quach H; Delarue R; Glaisner S; Gabarre J; Bosly A; Lister J; Li J; Coiffier B
Eur J Cancer; 2013 Sep; 49(13):2869-76. PubMed ID: 23731832
[TBL] [Abstract][Full Text] [Related]
20. Therapy refractory angioimmunoblastic T-cell lymphoma in complete remission with lenalidomide.
Beckers MM; Huls G
Eur J Haematol; 2013 Feb; 90(2):162-3. PubMed ID: 23227803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
